Navigation Links
FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
Date:1/23/2010

SILVER SPRING, Md., Jan. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

MS is a chronic, often disabling, disease that affects the central nervous system—the brain, spinal cord, and optic nerves. There are about 400,000 people in the United States and 2.5 million people world-wide with MS.

The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. Symptoms can be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. About half of all people with MS experience cognitive impairments like difficulties in concentration, attention, memory, and judgment, although these symptoms are usually mild and are frequently overlooked. Depression also is common among MS patients.

"Trouble with walking is one of the most debilitating problems people with MS face," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research.

Ampyra, when given at doses greater than that recommended (10 milligrams twice a day), can cause seizures. The most common adverse reactions reported by patients taking Ampyra in clinical trials include urinary tract infection, insomnia, dizziness, headache, nausea, weakness, back pain, balance disorder, swelling in the nose or throat, constipation, diarrhea, indigestion, throat pain, and burning, tingling or itching of skin.

Ampyra should not be used in patients with moderate to severe kidney disease. In these patients, blood levels with the drug approach those associated with the occurrence of seizures.

Ampyra will be manufactured under licenses from Elan of Dublin, Ireland, and distributed by Acorda Therapeutics Inc. of Hawthorne, N.Y.

For information about FDA drug approvals: http://www.fda.gov/Drugs/default.htm.

Contact: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older
2. FDA Approves Lillys ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
3. FDA Approves Lillys Zyprexa for Two Adolescent Indications
4. US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
5. FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus
6. FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn
7. FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
8. FDA Approves Agriflu Seasonal Influenza Vaccine
9. FDA Approves Lysteda to Treat Heavy Menstrual Bleeding
10. Rogan-Delft Approves Matrox Xenia Series for Use With Zillion Suite
11. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 /PRNewswire/ ... Annual Clinical and Scientific Meeting— OBP Medical , a ... today announced the launch of a new extra-small size ... and ER-SPEC vaginal specula. Already available in ... extra-large sizes makes OBP Medical,s line of single-use lighted ...
Breaking Medicine Technology:
(Date:5/29/2017)... CT (PRWEB) , ... May 29, 2017 , ... ... to announce a new training program for Recovery Coaches who are seeking opportunities ... emergency rooms, court systems, treatment centers, and others. Recovery Coaching and Professionalism© was ...
(Date:5/29/2017)... Pittsburgh, PA (PRWEB) , ... May 29, 2017 , ... ... seemingly simple question: How do doctors determine if someone is cured? The virus has ... the most expensive and time-consuming tests. , Scientists at the University of Pittsburgh’s Graduate ...
(Date:5/28/2017)... ... 2017 , ... Viewers likely know Rob Lowe from such 80s hits as ... his work on NBC’s The West Wing and Parks and Recreation. But recently, Lowe’s ... which puts the spotlight on important modern-day issues that face today’s society. One of ...
(Date:5/27/2017)... ... ... Most us are familiar with the sound of occasional popping joints that ... shows that certain people who experience consistent joint popping, grating and grinding are ... opportunity to treat patients before the problem becomes pronounced, potentially hedging off more severe ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s Algovita® ... Algovita SCS System has been FDA approved as a treatment option for chronic intractable ... the most powerful SCS system and the only stretchable lead on the market. This ...
Breaking Medicine News(10 mins):